Date: 1st April, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
BSE Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Alembic Pharmaceuticals receives one US Food & Drug Administration (USFDA) product approval (Tentative) during the quarter ended 31st March, 2024.

With reference the captioned subject, this is to inform the exchange that the Company has received one US Food & Drug Administration (USFDA) Product Approval (Tentative) during the quarter ended 31st March, 2024.

The summary statement giving brief of the product approval received during the quarter ended 31st March, 2024 is enclosed for your information and records.

Alembic has a cumulative total of 197 ANDA approvals (170 final approvals and 27 tentative approvals) from USFDA.

We request you to kindly take the above on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Digitally signed by Manisha Saraf
Date: 2024.04.01 11:41:52 +05'30'

Manisha Saraf
Company Secretary

Encl: A/a.

Annexure

Summarised Product Approval received during the quarter ended 31st March, 2024.

Product Name	Approval Final/ Tentative	Innovator Name	Brand name	Indication*
Ribociclib Tablets, 200 mg.	Tentative	Novartis Pharmaceuticals Corporation	Kisqali Tablets	Ribociclib tablet indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy.